DE3788847D1 - Hybrid-Promotor, expressionskontrollierende DNS-Sequenz und Expressions-Vektor. - Google Patents

Hybrid-Promotor, expressionskontrollierende DNS-Sequenz und Expressions-Vektor.

Info

Publication number
DE3788847D1
DE3788847D1 DE87402542T DE3788847T DE3788847D1 DE 3788847 D1 DE3788847 D1 DE 3788847D1 DE 87402542 T DE87402542 T DE 87402542T DE 3788847 T DE3788847 T DE 3788847T DE 3788847 D1 DE3788847 D1 DE 3788847D1
Authority
DE
Germany
Prior art keywords
expression
dna sequence
hybrid promoter
expression vector
controlling dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE87402542T
Other languages
English (en)
Other versions
DE3788847T2 (de
Inventor
Tatsurou Shibui
Michiru Kamizono
Yutaka Teranishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Kasei Corp
Original Assignee
Mitsubishi Kasei Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Kasei Corp filed Critical Mitsubishi Kasei Corp
Application granted granted Critical
Publication of DE3788847D1 publication Critical patent/DE3788847D1/de
Publication of DE3788847T2 publication Critical patent/DE3788847T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE19873788847 1986-11-11 1987-11-10 Hybrid-Promotor, expressionskontrollierende DNS-Sequenz und Expressions-Vektor. Expired - Fee Related DE3788847T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP61268362A JPS63123383A (ja) 1986-11-11 1986-11-11 ハイブリツドプロモ−タ−、発現調節ｄｎａ配列および発現ベクタ−

Publications (2)

Publication Number Publication Date
DE3788847D1 true DE3788847D1 (de) 1994-03-03
DE3788847T2 DE3788847T2 (de) 1994-05-05

Family

ID=17457465

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19873788847 Expired - Fee Related DE3788847T2 (de) 1986-11-11 1987-11-10 Hybrid-Promotor, expressionskontrollierende DNS-Sequenz und Expressions-Vektor.

Country Status (4)

Country Link
EP (1) EP0267851B1 (de)
JP (1) JPS63123383A (de)
CA (1) CA1309042C (de)
DE (1) DE3788847T2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE158816T1 (de) 1990-11-26 1997-10-15 Genetics Inst Expression von pace in wirtszellen und verfahren zu dessen verwendung
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US6444202B1 (en) 1996-11-25 2002-09-03 Bundesrepublic Deutschland, Vertreten Durch Den Bundesminister Fur Gesundheit Processed polypeptides with IL-16 activity, processes for their production and their use
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
ES2304065T3 (es) 1998-05-01 2008-09-01 Novartis Vaccines And Diagnostics, Inc. Antigenos y composiciones de neisseria meningitidis.
NZ581940A (en) 1999-04-30 2011-07-29 Novartis Vaccines & Diagnostic Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
RU2281956C2 (ru) 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
EP1195437A1 (de) * 2000-10-04 2002-04-10 Mitsui Chemicals, Inc. Verfahren zur rekombinanten Herstellung von Proteine durch Verwendung eines Plac/Np Hybrid-Promotor
EP2189473A3 (de) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nukleinsäure und Proteine von Gruppen A und B Streptokokken
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
JP4592284B2 (ja) 2001-07-27 2010-12-01 カイロン ソチエタ ア レスポンサビリタ リミタータ 髄膜炎菌付着因子
JP4413617B2 (ja) 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化
WO2003099854A2 (en) 2002-05-24 2003-12-04 Nps Allelix Corp. Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
EP1513945A4 (de) 2002-05-24 2008-12-24 Restoragen Inc Verfahren zur universellen enzymatischen herstellung bioaktiver peptide
DK2279746T3 (da) 2002-11-15 2013-11-25 Novartis Vaccines & Diagnostic Overfladeproteiner i neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
EP2392582A3 (de) 2003-04-25 2012-03-07 North Carolina State University Für kohlenhydratnutzende Verbindungen kodierende Nukleinsäurensequenzen aus Lactobacillus acidophilus, verwandte Proteine und Verwendungen davon
WO2005001057A2 (en) 2003-06-23 2005-01-06 North Carolina State University Lactobacillus acidophilus nucleic acids encoding fructo-oligosaccharide utilization compounds and uses thereof
ME01366B (me) 2003-11-21 2013-12-20 Nps Allelix Corp POSTUPAK ZA PROIZVODNJU PEPTIDA 2 NALIK NA GLUKAGON l NJIHOVIH ANALOGA
JP2007519422A (ja) 2004-02-02 2007-07-19 アンブレツクス・インコーポレイテツド 修飾されたヒト四螺旋バンドルポリペプチド及びそれらの使用
US7459289B2 (en) 2004-03-08 2008-12-02 North Carolina State University Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor
MXPA06014684A (es) 2004-06-18 2007-02-12 Ambrx Inc Novedosos polipeptidos de enlace antigeno y sus usos.
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
EP1871868A2 (de) 2005-04-15 2008-01-02 North Carolina State University Verfahren und zusammensetzungen zur modulation des haftvermögens und der stresstoleranz bei bakterien
EP2339014B1 (de) 2005-11-16 2015-05-27 Ambrx, Inc. Verfahren und Zusammensetzungen mit nichtnatürlichen Aminosäuren
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
EP2069396B1 (de) 2006-09-08 2015-10-21 Ambrx, Inc. Modifiziertes polypeptid oder fc-gerüste aus humanem plasma und ihre verwendung
BRPI0809583B1 (pt) 2007-03-30 2022-02-22 Ambrx, Inc Polipeptídeo fgf-21 modificado, composição compreendendo o mesmo, método para produzir o referido polipetídeo fgf-21 e célula compreendendo um polinucleotídeo
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
CA2716212A1 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
NZ591235A (en) 2008-07-23 2012-07-27 Ambrx Inc Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
PL2342223T3 (pl) 2008-09-26 2017-09-29 Ambrx, Inc. Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
TR201802361T4 (tr) 2008-09-26 2018-03-21 Ambrx Inc Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar.
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
EP2493499A1 (de) 2009-10-27 2012-09-05 Novartis AG Modifizierte meningokokken-fhbp-polypeptide
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
NZ600361A (en) 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
WO2011146715A1 (en) 2010-05-19 2011-11-24 North Carolina State University Compositions and methods for the delivery of therapeutic peptides
MY162837A (en) 2010-08-17 2017-07-31 Ambrx Inc Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
WO2015059690A1 (en) 2013-10-24 2015-04-30 Yeda Research And Development Co. Ltd. Polynucleotides encoding brex system polypeptides and methods of using s ame
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
US10590426B2 (en) 2016-08-22 2020-03-17 Board Of Trustees Of Michigan State University Genetic control of cell size
IL250479A0 (en) 2017-02-06 2017-03-30 Sorek Rotem Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
IL258467A (en) 2018-03-29 2018-07-04 Ilana Kolodkin Gal Methods of disrupting a biofilm and/or preventing formation of same
HRP20240016T1 (hr) 2018-09-11 2024-03-29 Ambrx, Inc. Konjugati polipeptida interleukina-2 i njihove uporabe
EP3946611A2 (de) 2019-03-31 2022-02-09 Yeda Research and Development Co. Ltd Antivirale und antitumorale verbindungen
WO2021183832A1 (en) 2020-03-11 2021-09-16 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
IL288680A (en) 2021-12-05 2023-07-01 Yeda Res & Dev Genetically modified phages and their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE237675C (de) *
US4495280A (en) * 1981-05-20 1985-01-22 The Board Of Trustees Of The Leland Stanford Jr. University Cloned high signal strength promoters
DD237675A1 (de) * 1981-07-27 1986-07-23 Liebscher Verfahren zur herstellung eines expressionsvektors
US4689406A (en) * 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
JPS60221091A (ja) * 1983-12-21 1985-11-05 Kyowa Hakko Kogyo Co Ltd 新規プロモ−タ−
GB8431818D0 (en) * 1984-12-17 1985-01-30 Bujard H Expression control sequence

Also Published As

Publication number Publication date
DE3788847T2 (de) 1994-05-05
EP0267851A3 (en) 1989-07-26
EP0267851A2 (de) 1988-05-18
CA1309042C (en) 1992-10-20
EP0267851B1 (de) 1994-01-19
JPS63123383A (ja) 1988-05-27

Similar Documents

Publication Publication Date Title
DE3788847D1 (de) Hybrid-Promotor, expressionskontrollierende DNS-Sequenz und Expressions-Vektor.
DE3670197D1 (de) Frisierstab.
DE3888381D1 (de) Hefevektor.
ES2012800B3 (es) Catalizadores de transformacion de hidrocarburos.
NO872075L (no) Herbicid-toleranse-kodende dna.
NO166779C (no) Passasjerbro.
FI870192A0 (fi) Nya tieno-1,4-diazepiner.
FI874690A (fi) Rumsenhet, i synnerhet kabin eller hytt pao fartyg.
DE3885543D1 (de) Dehydrierungskatalysator.
NO872174D0 (no) Polypetidpreparater med oekt biologisk tilgjengelighet.
FI884361A (fi) Foertjockad, vattenhaltig tvaettblandning innehaollande litet eller inget fosfat.
NO161463C (no) Hurtigflyvende legeme.
FI872044A (fi) Infaestningsanordning, foeretraedesvis foer doerrar, foenster eller dylikt.
DE3783176D1 (de) Bis-dioxopiperazin-abkoemmlinge.
FI861189A (fi) Foerstaerkningsfoerfarande och -anordning foer gas.
DE3787630D1 (de) Flugaschebehandlung.
FI851950A0 (fi) Saekerhetsbehaollare, saerskilt pengskrin eller kassaskaop.
DE3851139D1 (de) Tonikhaarlotion.
DE3767107D1 (de) Astigmatismus-generator.
FI901764A0 (fi) Syntetisk dna-sekvens, som kodar human insulinlik vaextfaktor ii.
FI885968A (fi) Haerdbara blandningar.
FI872465A (fi) Vektorer, vilka innehaoller vaermechockreglerande dna-sekvenser.
FI880952A0 (fi) Vaegg eller vaeggelement foer saekerhetsanordningar, saosom kassavalv, saekerhetsdoerrar, kassaskaop eller dylika.
NO872386L (no) Peptider.
DE3778970D1 (de) Benzenoxygenase-gen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee